INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
Sustainability in Drug Delivery
185
Issue No #185 Apr/May 2026
April 26th, 2026
Download PDF
Issue 185 - Apr/May 2026
Inside the magazine
SUSTAINABILITY
Serena Grace
Owen Mumford
REAL-TIME LCAs: CREATING “A SINGLE SOURCE OF TRUTH” FOR SUSTAINABILITY
Serena Grace and Marina Dumont offer insight into the development of a real-time operational model for lifecycle assessments, and detail how organisations can transform these analyses into robust decision-making tools.
EXPERT VIEW
Henryk Badack
MAINTAINING RELIABLE DRUG DELIVERY THROUGH SUSTAINABLE OPERATIONS
Henryk Badack considers how a holistic approach to sustainability can enable CDMOs to implement efficient operations strategically – while introducing initiatives that address environmental, economic and social elements.
EXPERT VIEW
Kiara Taylor
LATE-STAGE MATERIAL SUBSTITUTION: AMBITION FOR SUSTAINABILITY OR TRANSFER-TIME RISK?
Kiara Taylor delves into the challenges of changing materials to enhance sustainability after a design has been transferred to manufacturing, considering the reasons that might drive such a change, the issues involved and the benefits that can be gained.
SUSTAINABILITY
Nadine Kaufmann
Ypsomed
BIO-BASED PLASTICS IN DRUG DELIVERY: FROM MATERIAL EQUIVALENCE TO SYSTEMIC DECARBONISATION
Nadine Kaufmann and Michael Schori analyse the feasibility of introducing sustainable materials within current regulatory frameworks, demonstrating this with a range of Ypsomed products and illustrating ways to further integrate sustainable principles into the value chain.
EXPERT VIEW
Adam Tilley
SUSTAINABILITY IN DRUG DELIVERY
Adam Tilley and David Cook explore how carbon footprint considerations can be integrated into the drug delivery device design lifecycle, highlighting key sustainability decisions faced by design engineers and emerging tools that support those evaluations.
INTERVIEW
Prof Hanns-Christian Mahler
ten23 health
Exclusive Interview: Taking Sustainability Beyond Compliance
Prof Hanns-Christian Mahler engages in a wide-ranging discussion about current challenges and trends in the drug delivery industry, particularly on the topic of sustainability – it’s advantages, difficulties and why companies should aim to do more than the bare minimum required by the regulation.
SUSTAINABILITY
Dr Bernd Garska
Covestro LLC
RETHINKING DRUG DELIVERY: ENABLING RECYCLING AND MATERIAL EFFICIENCY IN HEALTHCARE
Dr Bernd Garska and Sven Schlecht highlight how single-use drug delivery devices can be re-thought to help solve the climate and environmental challenges in the healthcare sector.
SUSTAINABILITY
Lionel Maritan
ARaymond
ECO-DESIGN DRIVING NEST AND READY-TO-USE PACKAGING INNOVATION
Lionel Maritan and François Ciavatti discuss RayDyLyo
®
, an eco-designed nest developed to reduce the overall impact of ready-to-use components, reflecting on insights gained from lifecycle assessments, outlining the progress still to be made and illustrating how a pragmatic, inventive, eco-centric design approach can drive the development of packaging solutions with a measurably lower environmental footprint.
EXPERT VIEW
Greg Anderson
CHALLENGES & OPPORTUNITIES TO OPTIMISE SUSTAINABILITY IN PHARMACEUTICAL PACKAGING & COMBINATION DEVICES
Greg Anderson discusses the need to improve the sustainability and circularity of pharmaceutical packaging and drug delivery devices, looking at the challenges and providing a clear outline of the potential opportunities for improvement.
SUSTAINABILITY
Chris Baron
Aptar Pharma
REINVENTING THE pMDI: EVOLVING A PROVEN PLATFORM FOR A LOW-GWP FUTURE
Chris Baron discusses how lower-global warming potential pressurised metered dose inhalers are moving from development to commercialisation and explains why manufacturing readiness and supply resilience are critical, going on to introduce Aptar Pharma’s ZEN30 Futurity
®
, designed to anticipate current and emerging regulatory expectations.
EXPERT VIEW
Markus Laubscher
ENABLING A SUSTAINABLE FUTURE FOR pMDIs WITH LOW-GWP MEDICAL PROPELLANTS
Markus Laubscher discusses the role of pressurised metered dose inhalers in the context of healthcare’s drive towards sustainability, considering the need for lower-global-warming-potential propellants and why it is important to preserve these inhalers as a key aspect of respiratory care.
Top
